Biosimilars in India: Regulatory Landscape and Market Opportunities

India's Biosimilar Advantage

India has emerged as the world's largest manufacturer of biosimilars, with over 100 approved products. The country's combination of scientific talent, manufacturing scale, and cost efficiency positions it uniquely in the global biologics market.

Regulatory Framework

CDSCO's "Guidelines on Similar Biologics" (2016, updated 2023) established a regulatory pathway that balances scientific rigor with accessibility. Key requirements include comparative quality studies, non-clinical evaluation, and clinical trials demonstrating biosimilarity.

Market Dynamics

The Indian biosimilar market is valued at approximately USD 4.5 billion in 2026, growing at 22% CAGR. Key therapeutic areas include oncology (trastuzumab, bevacizumab, rituximab), autoimmune diseases (adalimumab), and diabetes (insulin glargine, insulin aspart).